Formulary guidance and transparency from P&T to point of care

Trends That Matter for HGH Treatments

Posted by Matt Breese on Jan 11, 2018

Find me on:


In our weekly Trends that Matter series, we provide infographics, articles and recent news from healthcare influencers to highlight general trends affecting the pharmaceutical industry. This week's featured topic is human growth hormone (HGH) treatments. 

According to our recent payer coverage analysis for HGH treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

Here are some recent trends:

  • Long Acting and Daily Differentiation? | The Growth Hormone Research Society recently published some research around long acting human growth hormone formulations. While these findings are still under review, many studies revealed that treatment responses were vastly similar to daily HGH products. However, some safety concerns were highlighted, as safety notes are typically exclusive to a single LAGH treatment.
  • Biobetters in Play | Manufacturers developing long-acting biobetters expect to introduce new growth hormones by the end of the year. A global report predicts that the market will reach $1.88 billion by 2024 with novel biobetters seizing market share from daily recombinant growth hormones during that time.

To learn more about this topic, download MMIT's Reality Check on Growth Hormone Treatment by clicking on the button below: 

View Reality Check 

Topics: Market Access, Data & Analytics